MassMutual Private Wealth & Trust FSB Has $80,000 Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• MassMutual Private Wealth & Trust FSB significantly reduced its stake in Zimmer Biomet Holdings, Inc. by 96.7% during the second quarter, holding only 880 shares valued at $80,000 after selling 25,508 shares.
• Several hedge funds have increased their positions in Zimmer Biomet, with notable acquisitions including OneDigital Investment Advisors LLC's new position worth $269,000 and Keybank National Association OH boosting its holdings by 61.2% to own 14,315 shares valued at $1,620,000.
• The company recently announced a quarterly dividend of $0.24 per share, with an annual yield of 1%, to be paid on October 31st to shareholders of record on September 30th.

MassMutual Private Wealth & Trust FSB trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 96.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 880 shares of the medical equipment provider's stock after selling 25,508 shares during the quarter. MassMutual Private Wealth & Trust FSB's holdings in Zimmer Biomet were worth $80,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $204,000. Two Sigma Investments LP acquired a new stake in Zimmer Biomet during the 4th quarter worth about $4,085,000. Neo Ivy Capital Management boosted its position in Zimmer Biomet by 371.7% during the 4th quarter. Neo Ivy Capital Management now owns 6,528 shares of the medical equipment provider's stock worth $689,000 after acquiring an additional 5,144 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Zimmer Biomet during the 4th quarter worth about $518,000. Finally, North Star Asset Management Inc. boosted its position in Zimmer Biomet by 6.0% during the 4th quarter. North Star Asset Management Inc. now owns 3,163 shares of the medical equipment provider's stock worth $334,000 after acquiring an additional 180 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded up $1.81 on Monday, reaching $101.90. 1,531,577 shares of the stock were exchanged, compared to its average volume of 1,984,251. The stock has a market cap of $20.19 billion, a PE ratio of 24.79, a PEG ratio of 2.30 and a beta of 0.68. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72. The firm has a fifty day moving average price of $100.06 and a two-hundred day moving average price of $99.35.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several research reports. Rothschild Redb upgraded shares of Zimmer Biomet to a "strong-buy" rating in a report on Thursday. Royal Bank Of Canada lifted their target price on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research report on Thursday. UBS Group lifted their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research report on Friday, August 8th. Finally, Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a report on Thursday. They set a "buy" rating and a $130.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $113.16.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.70% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.